
all rights reserved © science photo
Researchers at the University of Michigan have identified a promising new drug compound for targeting one of the most aggressive types of breast cancer. The compound, currently called UM-164, goes after a kinase known to play a role in the growth and spread of triple-negative breast cancer. UM-164 blocks the kinase c-Src and inhibits another pathway, p38, involved in this subtype. The researchers found that the compound had very few side effects in mice.
Leave a Reply